abstract Biologics have been a key component of severe asthma treatment, and there are
currently biologics available that target IgE, IL-5, IL-4/IL-13, and TSLP. Randomized …

Severe asthma is a heterogeneous disease with different phenotypes based on clinical,
functional or inflammatory parameters. In particular, the eosinophilic phenotype is …

Background Dupilumab as add-on treatment for severe uncontrolled asthma (SA) has
shown to be effective and safe by phase-III-trials. Real-world data on clinical efficacy and …

Abstract Background Omalizumab and Mepolizumab are biologic drugs with proven efficacy
in clinical trials. However, a better understanding of their real‐world effectiveness in severe …

Although there is still no consensus on the definition of Asthma-COPD Overlap (ACO), it is
generally accepted that some patients with airway disease have features of both asthma and …

Severe asthma in children and adolescents exerts a substantial health, financial, and
societal burden. Severe asthma is a heterogeneous condition with multiple clinical …

In recent years, the more widespread availability of biological drugs with specific
mechanisms of action has led to significant breakthroughs in the management of severe …

Objective Benralizumab is a promising drug for severe uncontrolled asthma. This study
aimed to clarify the effectiveness of benralizumab in a real-life setting. Methods Subjects …

Background Oral corticosteroids (OCS) carry serious health risks. Innovative treatment
options are required to reduce excessive exposure and promote OCS stewardship …

Purpose The German Asthma Net (GAN) operates a Severe Asthma Registry that provides
an overview of the clinical presentation and management of patients with severe asthma …